In-vitro activities of voriconazole, itraconazole and Amphotericin B against Aspergillus species

O. C. Abraham, Elias Kurian Manavathu, P. H. Chandrasekar

Research output: Contribution to journalArticlepeer-review


In vitro susceptibility testing for filamentous fungi is under development. Using the broth macrodilution method, we compared the in vitro activities of Voriconazole (VCZ), Itraconazole (ITZ) and Amphotericin B (AB) against 216 clinical isolates of Aspergillus spp. (142 isolates of A. fumigatus and 74 of non-fumigatus Aspergillus spp.). 0.5 ml of PYG medium (1 g peptone, 1 g yeast extract and 3 g dextrose per liter distilled water) with various concentrations of the antifungal drug and 0.5 ml conidial suspension (1 × 104 cfu/ml) was incubated at 37 °C for 48 h and MIC endpoints were read visually. The MIC in micrograms/ml (mean+/-SD, range) for A. fumigatus were as follows: VCZ 0.88+/-0.54,0.25-4; ITZ 0.54+/-0.46,0.25-4; AB 2.16+/-1.64, 0.5-8. MIC90 were as follows: VCZ 2, ITZ 1, AB 4. MICs for non-fumigatus Aspergillus spp. were: VCZ 1.57+/-1.17, 0.25-4; ITZ 1.74+/-1.63,0.25-4; AB 2.88+/-1.47,0.5-8. MIC90 for this group were: VCZ 4, ITZ 4, AB 4.The mean MICs of azoles (VCZ and ITZ) were 2 3 times higher for the non-fumigatus Aspergillus spp. Our study shows that VCZ is as effective as ITZ and AB against Aspergillus (fumigatus and non-fumigatus spp.) in vitro and that non-fumigatus Aspergillus is less susceptible than A. fumigatus to the azole antifungals tested.

Original languageEnglish (US)
Number of pages1
JournalClinical Infectious Diseases
Issue number2
StatePublished - Dec 1 1997

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'In-vitro activities of voriconazole, itraconazole and Amphotericin B against Aspergillus species'. Together they form a unique fingerprint.

Cite this